| Exudative age-related macular degeneration
Cimerli vs Byooviz
Side-by-side clinical, coverage, and cost comparison for exudative age-related macular degeneration.Deep comparison between: Cimerli vs Byooviz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsByooviz has a higher rate of injection site reactions vs Cimerli based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Byooviz but not Cimerli, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cimerli
Byooviz
At A Glance
Intravitreal injection
Monthly
VEGF-A antagonist
Intravitreal injection
Monthly
VEGF-A antagonist
Indications
- Exudative age-related macular degeneration
- Retinal Vein Occlusion
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Myopic choroidal neovascularization
- Exudative age-related macular degeneration
- Retinal Vein Occlusion
- Myopic choroidal neovascularization
Dosing
Exudative age-related macular degeneration 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); alternatively, 3 monthly doses followed by less frequent dosing, or one dose every 3 months after 4 monthly doses, with regular assessment.
Retinal Vein Occlusion 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days).
Macular edema due to diabetes mellitus, Diabetic Retinopathy 0.3 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days).
Myopic choroidal neovascularization 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days) for up to 3 months; may be retreated if needed.
Exudative age-related macular degeneration 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); may reduce to less frequent dosing after 3 initial monthly doses with regular assessment, or once every 3 months after 4 monthly doses.
Retinal Vein Occlusion 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); patients should be treated monthly.
Myopic choroidal neovascularization 0.5 mg (0.05 mL) by intravitreal injection once monthly for up to 3 months; retreatment as needed.
Contraindications
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab products or any excipient in CIMERLI
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab products or any excipient in BYOOVIZ
Adverse Reactions
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, vitreous detachment, cataract, nasopharyngitis, anemia, nausea, cough
Serious Endophthalmitis, retinal detachment, increased intraocular pressure, thromboembolic events, rhegmatogenous retinal detachment, iatrogenic traumatic cataract
Postmarketing Tear of retinal pigment epithelium (patients with neovascular AMD)
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, intraocular pressure increased, vitreous detachment, intraocular inflammation, cataract, nasopharyngitis, headache, bronchitis, arthralgia, upper respiratory tract infection
Serious Endophthalmitis, retinal detachments, thromboembolic events, serious intraocular inflammation
Postmarketing Tear of retinal pigment epithelium (neovascular AMD patients)
Pharmacology
Ranibizumab-eqrn is a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in ocular conditions.
VEGF-A antagonist; ranibizumab products bind to the receptor binding site of active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cimerli
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
Byooviz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Cimerli
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Byooviz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cimerli
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Byooviz
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: Macular Disease
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableByooviz Administration Copay Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CimerliView full Cimerli profile
ByoovizView full Byooviz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.